Overview

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Status:
Withdrawn

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

To determine the recommended phase 2 dose of chemotherapy in combination with Pembrolizumab in subjects with advanced lymphoma and determine the complete response rate.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Western Regional Medical Center

Treatments:

Antibodies, Monoclonal
Brentuximab Vedotin
Carboplatin
Etoposide
Etoposide phosphate
Ifosfamide
Isophosphamide mustard
Pembrolizumab
Rituximab